



Commonwealth of Massachusetts  
**MassHealth Drug Utilization Review Program**  
 P.O. Box 2586, Worcester, MA 01613-2586  
**Fax:** (877) 208-7428      **Phone:** (800) 745-7318

## Immune Globulin Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at [www.mass.gov/druglist](http://www.mass.gov/druglist).

### Member information

Last name \_\_\_\_\_ First name \_\_\_\_\_ MI \_\_\_\_\_  
 MassHealth member ID # \_\_\_\_\_ Date of birth \_\_\_\_\_  
 Gender (Check one.)  F  M      Member's place of residence  home  nursing facility

### Medication information

#### Medication requested

- |                                     |  |                                    |                                   |
|-------------------------------------|--|------------------------------------|-----------------------------------|
| <input type="checkbox"/> Asceniv    | <input type="checkbox"/> Gamastan S/D  | <input type="checkbox"/> Gamunex-C | <input type="checkbox"/> Privigen |
| <input type="checkbox"/> Bivigam    | <input type="checkbox"/> Gammagard     | <input type="checkbox"/> Hizentra  | <input type="checkbox"/> Xembify  |
| <input type="checkbox"/> Cutaquig   | <input type="checkbox"/> Gammagard S/D | <input type="checkbox"/> Hyqvia    |                                   |
| <input type="checkbox"/> Cuvitru    | <input type="checkbox"/> Gammaked      | <input type="checkbox"/> Octagam   |                                   |
| <input type="checkbox"/> Flebogamma | <input type="checkbox"/> Gammaplex     | <input type="checkbox"/> Panzyga   |                                   |

**Dose of medication requested** \_\_\_\_\_ mg per kg = \_\_\_\_\_ g

**Frequency and duration of medication requested** \_\_\_\_\_

Please specify dosing schedule.  Scheduled  Intermittent

Member's current actual body weight (ABW) \_\_\_\_\_ Date \_\_\_\_\_

Member's current height \_\_\_\_\_ Date \_\_\_\_\_

Member's current Body Mass Index (BMI) \_\_\_\_\_ Date \_\_\_\_\_

For initiation of intravenous immune globulin (IVIG), if a member's BMI is  $\geq 30 \text{ kg/m}^2$  or ABW is  $> 120\%$  of ideal body weight (IBW), dosing calculated using adjusted body weight has been demonstrated to have similar clinical effect as using ABW. MassHealth suggests the use of this dosing strategy to promote cost effective care. This is not meant to replace clinical decision making when initiating medication therapy.

Please complete the below question.

If member meets the criteria noted above (BMI  $\geq 30 \text{ kg/m}^2$  or ABW  $> 120\%$  of IBW), is the member a candidate for adjusted body weight dosing? If criteria are not applicable, this may be left blank.

Yes. MassHealth to calculate total dose based on adjusted body weight\* (may round dose to vial size).

No. Please explain why adjusted body weight\* dosing is not appropriate for this member. \_\_\_\_\_

\* *Adjusted Body Weight = IBW + 0.4 (ABW - IBW)*

Please indicate billing preference.  Pharmacy  Prescriber in-office  Hospital outpatient

For hospital outpatient billing, provide department-specific facility NPI \_\_\_\_\_

Drug NDC (if known) or service code \_\_\_\_\_

**Is the member stabilized on the requested medication?**

Yes. Please provide start date. \_\_\_\_\_  No

---

**Section I. Please specify the indication for all requests. For Asceniv requests, please also complete Section II as appropriate.**

Primary immunodeficiency disorders (PID)

Please attach laboratory documentation supporting diagnosis.

Provide date and results of most recent serum immunoglobulin levels (including laboratory reference ranges).

\_\_\_\_\_

Immune thrombocytopenia (ITP)

Provide date and results of most recent platelet count (including laboratory reference ranges).

\_\_\_\_\_

Is the member actively bleeding?  Yes. Please describe below.  No

\_\_\_\_\_

Does the member have a history of or risk of significant bleeding?  Yes. Please describe below.  No

\_\_\_\_\_

Kawasaki disease (mucocutaneous lymph node syndrome)

Provide date of onset. \_\_\_\_\_

B-cell chronic lymphocytic leukemia (CLL)

Chronic inflammatory demyelinating polyneuropathy (CIDP)

Multifocal motor neuropathy (MMN)

Other \_\_\_\_\_

Please describe the medical necessity for the use of immune globulin including previous trials and outcomes.

\_\_\_\_\_

\_\_\_\_\_

---

**Section II. Please also complete for requests for Asceniv. Please complete Section I above as appropriate.**

Please provide clinical rationale for the use of this product over other available IVIG products.

\_\_\_\_\_

\_\_\_\_\_

---

**Section III. Please complete for all requests for non-preferred drug products if one or more preferred drug products have been designated for this class of drugs.**

If one or more preferred drug products have been designated for this class of drugs, and if you are requesting PA for a non-preferred drug product, please provide medical necessity for prescribing the non-preferred drug product rather than the preferred drug product.

\_\_\_\_\_

\_\_\_\_\_

---

**Prescriber information**

Last name\* \_\_\_\_\_ First name\* \_\_\_\_\_ MI \_\_\_\_\_  
NPI\* \_\_\_\_\_ Individual MH Provider ID \_\_\_\_\_  
DEA No. \_\_\_\_\_ Office Contact Name \_\_\_\_\_  
Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
E-mail address \_\_\_\_\_  
Telephone No.\* \_\_\_\_\_ Fax No.\* \_\_\_\_\_

\* *Required*

---

**Prescribing provider's attestation, signature, and date**

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

**Signature required** \_\_\_\_\_

Printed name of prescribing provider \_\_\_\_\_ Date \_\_\_\_\_